Please assess the completion status of the following clinical trial:

Trial Title: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed classical Hodgkin lymphoma (HL) meeting the following criteria:~  * Meets current WHO classification criteria (i.e., nodular sclerosis, mixed cellularity, lymphocyte rich, and lymphocyte-depleted)~ * Clinical stage IIB, III, or IV disease OR clinical stage IIA disease with adverse features, including any of the following:~    * Bulk mediastinal disease, defined as maximal transverse diameter of mass \> 0.33 of the internal thoracic diameter at D5/6 interspace on routine chest x-ray~   * Disease outside the mediastinum and lymph node or lymph node mass \> 10 cm in diameter~   * More than two sites of disease~   * Other poor-risk features that require treatment with full course combination chemotherapy~* Newly diagnosed disease~* No CNS or meningeal involvement by lymphoma~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Life expectancy \> 3 months~* ANC \> 1,500/mm\^3 (unless there is bone marrow infiltration by lymphoma)~* Platelet count \> 100,000/mm\^3 (unless there is bone marrow infiltration by lymphoma)~* Creatinine \< 150% of upper limit of normal (ULN)~* Bilirubin \< 2.0 times ULN (unless attributed to lymphoma)~* Transaminases \< 2.5 times ULN (unless attributed to lymphoma)~* LVEF ≥ 50% (in patients with a significant history of ischemic heart disease or hypertension)~* Diffusion capacity within 25% of normal predicted value by lung function testing~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Amenable to the administration of a full course of chemotherapy, according to the investigator~* Must have access to PET/CT scanning~* No poorly controlled diabetes mellitus~* No cardiac contraindication to doxorubicin hydrochloride, including abnormal contractility by ECHO or MUGA~* No neurological contraindication to chemotherapy (e.g., pre-existing neuropathy)~* No other concurrent uncontrolled medical condition~* No other active malignant disease within the past 10 years, except fully excised basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix~* No known positivity for HIV, hepatitis B surface antigen, or hepatitis C~  * Routine testing, in the absence of risk factors, is not required~* No medical or psychiatric condition that compromises the patient's ability to give informed consent~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy, radiotherapy or other investigational drug for HL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: ACTIVE_COMPARATOR): Patients receive AVD chemotherapy comprising doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
- BEACOPP-14 chemotherapy (Type: EXPERIMENTAL): Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride and oral prednisolone on days 1-7; and bleomycin IV and vincristine IV on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 8-13 OR pegfilgrastim SC once on day 8. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
- BEACOPP-escalated chemotherapy (Type: EXPERIMENTAL): Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride on days 1-7; oral prednisolone on days 1-14; and bleomycin IV and vincristine IV on day 8. Patients also receive G-CSF SC beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete